A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

计划入组 6 人 · 首次发布于 2024 年 2 月 12 日

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)

计划入组 7 人 · 首次发布于 2024 年 3 月 5 日

Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA)

计划入组 5 人 · 首次发布于 2026 年 6 月 5 日

Undisclosed,Electra Therapeutics Inc(T Cell Mediated Autoimmune Diseases)

anti-CD19 CAR T cell therapy (B-cell mediated autoimmune disease)

Autoimmune diseases(Waypoint)

Cabaletta Bio

United States

Autoimmune Technologies, LLC

United States

AB&B BIO-TECH-B

Sana Biotechnology Focuses on Immunologic Diseases, Advances Clinical Programs

Sana Biotechnology Focuses on Immunologic Diseases, Reports Q3 2024 Results

WuXi Biologics Partners with Vertex on Trispecific T-Cell Engager for Autoimmune Diseases